Compare PPTA & AMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PPTA | AMRX |
|---|---|---|
| Founded | 2011 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 3.7B |
| IPO Year | 2011 | 2018 |
| Metric | PPTA | AMRX |
|---|---|---|
| Price | $29.03 | $12.36 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $36.17 | $14.75 |
| AVG Volume (30 Days) | 1.5M | ★ 1.7M |
| Earning Date | 05-11-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 157.89 |
| EPS | N/A | ★ 0.22 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $4.48 |
| Revenue Next Year | N/A | $7.13 |
| P/E Ratio | ★ N/A | $56.09 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.75 | $6.69 |
| 52 Week High | $37.37 | $15.42 |
| Indicator | PPTA | AMRX |
|---|---|---|
| Relative Strength Index (RSI) | 51.50 | 45.20 |
| Support Level | $23.55 | $11.60 |
| Resistance Level | $30.77 | $12.85 |
| Average True Range (ATR) | 1.78 | 0.34 |
| MACD | 0.36 | 0.10 |
| Stochastic Oscillator | 83.28 | 65.52 |
Perpetua Resources Corp is focused on the exploration, site restoration, and redevelopment of gold-antimony-silver deposits in the Stibnite-Yellow Pine district of central Idaho that are encompassed by the Stibnite Gold Project. The Project is one of the highest-grade, open-pit gold deposits in the United States and is designed to apply a modern, responsible mining approach to restore an abandoned mine site and produce both gold and the only mined source of antimony in the United States. It has one segment, mineral exploration in the United States.
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE. It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment, which derives maximum revenue, focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.